Diligence memo · auto-generated · as of July 2, 2026

Altheus Therapeutics Inc

Altheus Therapeutics Inc looks fair against its niche peers and is dormant on financing cadence.

DeprioritizeFinancing has gone silent well past the sector's normal cadence — treat as inactive until outside confirmation of a live operation.

Businessfiled

Altheus Therapeutics Inc operates in Biotechnology, based in OKLAHOMA CITY.

No verified homepage on file yet — operating evidence is limited to the public record.

Capital & rounds (filed)filed

Altheus Therapeutics Inc has raised $33M in disclosed capital across 9 recorded rounds, aggregated from public filings. Its latest round is modeled as Series A (a $4.0M–$15M round).

Largest single filing: $8.1M on 2012-02-24.

Most recent recorded round closed around 2012-02-24.

Valuation (modeled)modeled

Provath models Altheus Therapeutics Inc at approximately $292M (range $8.8M–$1.6B). This is an algorithmic estimate from round sizes and same-niche peers — not a quoted or reported figure.

Read: Fair. Modeled value is 1.46× the median modeled value of Series A Biotechnology companies in 2010–2012 (92 peers) — value vs value, same stage and era. Within the normal band (146% of peer median) for its niche.

Financing rhythm & timingmixed

Historic cadence: a new round about every 4 months.

Last raise 14.4 yr ago; this sector typically re-raises about every 14 months.

Silent for over 3× the sector's normal cadence.

The last round stepped up 1.5× from the prior — scaling.

Comparablesmixed

Capital scale ranks ahead of 76% of Biotechnology peers (4293 compared).

Modeled value ranks above 76% of those peers.

Closest niche peers: Tobira Therapeutics, Inc., Neoprobe Corp, Akebia Therapeutics, Inc., Adimab, LLC, Elevation Pharmaceuticals Inc.

Peoplefiled

12 named people on file across officers, directors and signatories.

Risks & flagsmixed

Financing has been silent well beyond sector cadence — possibly defunct, acquired, or paused.

No clearly named CEO/founder/principal in the surfaced records — key-person evidence is thin.